Domingues Sol Lara, Gonçalves Fabrícia Torres, Jorge Maria Luiza Mendonça Pereira, Limongi Jean Ezequiel, Ranza Roberto, Jorge Paulo Tannus
Endocr Pract. 2017 Nov;23(11):1304-1310. doi: 10.4158/EP161664.OR. Epub 2017 Aug 17.
Because routine investigations are necessary for the early detection of thyroid disease, this study aimed to assess the prevalence of autoimmune thyroid disease (ATD) and thyroid dysfunction (TD) in patients with systemic lupus erythematosus (SLE).
Seventy-nine SLE patients (American College of Rheumatology criteria) and 159 control patients with no diagnosis of autoimmune diseases (except for ATD) were consecutively evaluated regarding changes in laboratory assessments of thyroid function and the presence of ATD.
ATD was detected in 11.4% of the SLE patients and 13.8% of the control patients (P = .747), whereas TD was detected in 25.3 and 9.4% (P = .002), hypothyroidism was detected in 21.5 and 6.9% (P = .002), and hyperthyroidism was detected in 3.8 and 2.5% (P = .426) of the SLE and control patients, respectively. The mean duration of SLE was longer in patients with TD (P = .036). Mild hypothyroidism was more frequent in the SLE patients with anti-Smith antibodies (P = .029).
Because hypothyroidism was more frequent in SLE patients and the frequency of ATD was high in both groups, the authors suggest that TSH and anti-thyroid antibody levels be assessed in SLE patients.
ACA = anti-cardiolipin antibodies; ANF = anti-nuclear factor; anti-CCP = anti-cyclic citrullinated peptide; anti-dsDNA = anti-double-stranded DNA; anti-RNP = anti-ribonucleoprotein; anti-Scl70 = anti-topoisomerase I antibodies; anti-SM = anti-Smith antigen antibodies; anti-SS-A/Ro = anti-Sjögren syndrome-related antigen A (Ro); anti-SS-B/La = anti-Sjögren syndrome-related antigen B (La); anti-Tg = anti-thyroglobulin; anti-TPO = anti-thyroid peroxidase; ATD = autoimmune thyroid disease; ENA = extractable nuclear antigen; fT4 = free thyroxine; OR = odds ratio; RF = rheumatoid factor; SLE = systemic lupus erythematosus; SLEDAI = SLE Disease Activity Index; TD = thyroid dysfunction; TSH = thyroid-stimulating hormone; TT3 = total triiodothyronine.
由于常规检查对于甲状腺疾病的早期发现至关重要,本研究旨在评估系统性红斑狼疮(SLE)患者中自身免疫性甲状腺疾病(ATD)和甲状腺功能障碍(TD)的患病率。
连续评估79例SLE患者(符合美国风湿病学会标准)和159例未诊断为自身免疫性疾病(ATD除外)的对照患者的甲状腺功能实验室评估变化及ATD的存在情况。
SLE患者中11.4%检测出ATD,对照患者中为13.8%(P = 0.747);而SLE患者和对照患者中TD的检出率分别为25.3%和9.4%(P = 0.002),甲状腺功能减退的检出率分别为21.5%和6.9%(P = 0.002),甲状腺功能亢进的检出率分别为3.8%和2.5%(P = 0.426)。TD患者的SLE平均病程更长(P = 0.036)。抗史密斯抗体阳性的SLE患者中轻度甲状腺功能减退更为常见(P = 0.029)。
由于SLE患者中甲状腺功能减退更为常见,且两组中ATD的发生率都较高,作者建议对SLE患者评估促甲状腺激素(TSH)和抗甲状腺抗体水平。
ACA = 抗心磷脂抗体;ANF = 抗核因子;抗CCP = 抗环瓜氨酸肽;抗双链DNA = 抗双链DNA;抗RNP = 抗核糖核蛋白;抗Scl70 = 抗拓扑异构酶I抗体;抗SM = 抗史密斯抗原抗体;抗SS - A/Ro = 抗干燥综合征相关抗原A(Ro);抗SS - B/La = 抗干燥综合征相关抗原B(La);抗Tg = 抗甲状腺球蛋白;抗TPO = 抗甲状腺过氧化物酶;ATD = 自身免疫性甲状腺疾病;ENA = 可提取核抗原;游离甲状腺素 = 游离甲状腺素;OR = 比值比;RF = 类风湿因子;SLE = 系统性红斑狼疮;SLEDAI = SLE疾病活动指数;TD = 甲状腺功能障碍;TSH = 促甲状腺激素;总三碘甲状腺原氨酸 = 总三碘甲状腺原氨酸